Litcius/Paper detail

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer

Xinhua Liu, Rongfang Qiu, Min Xu, Miaomiao Meng, Siyu Zhao, Jiansong Ji, Yang Yang

2021Breast Cancer Research and Treatment32 citationsDOI

Topics & Concepts

Breast cancerCarcinogenesisEpigeneticsCancer researchBiologyCancerBiomarkerOncologyMedicineGeneGeneticsEpigenetics and DNA MethylationMicroRNA in disease regulationHistone Deacetylase Inhibitors Research
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer | Litcius